This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Optimizing Ischemic Outcomes in ACS: Formulating Antiplatelet Therapies Across Complex Clinical Scenarios

Optimizing Ischemic Outcomes in ACS: Formulating Antiplatelet Therapies Across Complex Clinical Scenarios


Patient Case Study

Time to Complete

45 minutes


December 11, 2018


June 11, 2019
Add to Queue

Maximum Credits

0.75 / AMA PRA Category 1 CreditsTM

Accredited Provider

Provided by the Academy for Continued Healthcare Learning (ACHL).

Commercial Supporter

This activity is supported by an educational grant from AstraZeneca.

Program Description

This activity features symposium highlights from the C3 Advanced Endovascular and Coronary Intervention Global Summit, which took place June 2018 in Orlando, Florida. A panel of faculty experts discuss topics in ACS treatment optimization, including: Improving individualized dual antiplatelet regimens in complex patients; Performing genetic testing to guide DAPT; Weighing index lesion complexity versus patient characteristics to optimize DAPT benefits.

Intended Audience

This activity is intended for interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, technologists, nurses, and other clinicians who manage thrombotic risks across diverse patient populations.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the latest guidelines for antiplatelet therapy in ACS
  • Compare and contrast the pharmacodynamic properties of antiplatelet therapies
  • Outline the most recent efficacy and safety data of antiplatelet therapies and dual antiplatelet regimens for patients undergoing PCI
  • Discuss the advantages and challenges of maintaining longer term antiplatelet therapy for reduction of cardiovascular risk

Conflict Of Interest Disclosure Policy

ACHL requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. The following financial relationships have been provided:


Marc P. Bonaca, MD, MPH
Assistant Professor, Harvard Medical School
Associate Physician, Brigham and Women’s Hospital
Boston, MA

Dr. Bonaca discloses the following:
Consultant: Aralez, AstraZeneca, Bayer, Janssen, Merck
Research Support: MedImmune, Merck, Amgen, AstraZeneca

Bryan Kluck, DO
Lehigh Valley Health Network
Allentown, PA

Dr. Kluck discloses the following:
Board Member/Advisory Panel: Boston Scientific Corporation, Janssen
Speakers Bureau: Aralez, Boehringer Ingelheim

Sandeep Nathan, MD, MSc
Associate Professor of Medicine
Medical Director, Cardiac Intensive Care Unit
Director, Interventional Cardiology Fellowship Program
Co-Director, Cardiac Catheterization Laboratory
Heart and Vascular Center, University of Chicago Medicine
Chicago, IL

Dr. Nathan discloses the following:
Consultant: AstraZeneca, Cardiovascular Systems, Inc., Janssen, Maquet, Medtronic, Merit Medical, Terumo Medical Corporation
Speakers Bureau: Cardiovascular Systems, Inc., Janssen

Christian T. Ruff, MD, MPH
Assistant Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women's Hospital
Boston, MA

Dr. Ruff discloses the following:
Board Member/Advisory Panel: Bayer Healthcare, Boehringer Ingelheim, Daiichi Sankyo, Inc., Janssen, Portola
Consultant: Boehringer Ingelheim, Daiichi Sankyo, Inc.
Research Support: Boehringer Ingelheim, Daiichi Sankyo, Inc., MedImmune, NIH

Accredited Provider Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of ACHL and Interventional Academy. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None


The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.


This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pre-test, view the activity, and complete the post-test and evaluation. To receive credit, 66% must be achieved on the post-test. A certificate will be immediately available. There is no fee for the generation of the certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please call ACHL at (877) 444-8435, ext. 125.


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue